Evidence map›Paper›PMID 38068945›Full record

ArticleInternational journal of molecular sciences2023

Enhancing Selectivity of Protein Biopharmaceuticals in Ion Exchange Chromatography through Addition of Organic Modifiers.

Bastiaan Laurens Duivelshof, Thomas Bouvarel, Sebastian Pirner, Vincent Larraillet, Alexander Knaupp, Hans Koll, Valentina D'Atri, Davy Guillarme

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Bastiaan Laurens DuivelshofSchool of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland.
Thomas BouvarelSchool of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland.ORCID 0000-0001-9128-3488
Sebastian PirnerRoche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.ORCID 0000-0002-7963-3059
Vincent LarrailletRoche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
Alexander KnauppRoche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
Hans KollRoche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
Valentina D'AtriSchool of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland.ORCID 0000-0002-2601-7092
Davy GuillarmeSchool of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland.ORCID 0000-0001-7883-5823
Roche Pharma AG (Germany) · DEUniversity of Geneva · CH

Funding

Roche Diagnostics GmbH xxx
6 · The paper itself

Abstract

Charge heterogeneity among therapeutic monoclonal antibodies (mAbs) is considered an important critical quality attribute and requires careful characterization to ensure safe and efficacious drug products. The charge heterogeneity among mAbs is the result of chemical and enzymatic post-translational modifications and leads to the formation of acidic and basic variants that can be characterized using cation exchange chromatography (CEX). Recently, the use of mass spectrometry-compatible salt-mediated pH gradients has gained increased attention to elute the proteins from the charged stationary phase material. However, with the increasing antibody product complexity, more and more selectivity is required. Therefore, in this study, we set out to improve the selectivity by using a solvent-enriched mobile phase composition for the analysis of a variety of mAbs and bispecific antibody products. It was found that the addition of the solvents to the mobile phase appeared to modify the hydrate shell surrounding the protein and alter the retention behavior of the studied proteins. Therefore, this work demonstrates that the use of solvent-enriched mobile phase composition could be an attractive additional method parameter during method development in CEX.

Indexed as

Biological ProductsAntibodies, MonoclonalChromatography, Ion ExchangeHydrogen-Ion ConcentrationIndicators and ReagentsSolventsAntibodies, MonoclonalBiological ProductsIndicators and ReagentsSolventsbispecific antibodyFab fragmention exchange chromatographymonoclonal antibodyorganic modifiersalt gradientsalt-mediated pH gradient

Identifiers

PMID38068945
PMCPMC10706461
OpenAlexW4388913062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.